{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T23:51:37Z","timestamp":1783813897480,"version":"3.55.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["NRF-2019R1A2C2002113"],"award-info":[{"award-number":["NRF-2019R1A2C2002113"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.canlet.2021.09.015","type":"journal-article","created":{"date-parts":[[2021,9,13]],"date-time":"2021-09-13T11:06:41Z","timestamp":1631531201000},"page":"44-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"C","title":["METTL3 induces PLX4032 resistance in melanoma by promoting m6A-dependent EGFR translation"],"prefix":"10.1016","volume":"522","author":[{"given":"Poshan Yugal","family":"Bhattarai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garam","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muna","family":"Poudel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6179-691X","authenticated-orcid":false,"given":"Sung-Chul","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7862-2342","authenticated-orcid":false,"given":"Hong Seok","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2021.09.015_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1261\/rna.054502.115","article-title":"Cracking the epitranscriptome","volume":"22","author":"Schwartz","year":"2016","journal-title":"RNA"},{"key":"10.1016\/j.canlet.2021.09.015_bib2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.tig.2019.10.011","article-title":"The biogenesis and precise control of RNA m6A methylation","volume":"36","author":"Huang","year":"2020","journal-title":"Trends Genet."},{"key":"10.1016\/j.canlet.2021.09.015_bib3","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41392-020-00450-x","article-title":"The role of m6A modification in the biological functions and diseases","volume":"6","author":"Jiang","year":"2021","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/j.canlet.2021.09.015_bib4","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1038\/s41467-019-10669-0","article-title":"m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade","volume":"10","author":"Yang","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2021.09.015_bib5","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/CMR.0000000000000580","article-title":"RNA m6A methyltransferase METTL3 regulates invasiveness of melanoma cells by matrix metallopeptidase 2","volume":"29","author":"Dahal","year":"2019","journal-title":"Melanoma Res."},{"key":"10.1016\/j.canlet.2021.09.015_bib6","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.09.015_bib7","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1073\/pnas.90.7.2960","article-title":"Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance","volume":"90","author":"Nyce","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.canlet.2021.09.015_bib8","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.molcel.2016.05.041","article-title":"Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases","volume":"63","author":"Wang","year":"2016","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2021.09.015_bib9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/nature18298","article-title":"Structural basis of N6-adenosine methylation by the METTL3\u2013METTL14 complex","volume":"534","author":"Wang","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.09.015_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.01403","article-title":"Multiple functions and mechanisms underlying the role of METTL3 in human cancers","volume":"9","author":"Zheng","year":"2019","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.canlet.2021.09.015_bib11","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2217\/epi-2019-0358","article-title":"RNA N-6-methyladenosine enzymes and resistance of cancer cells to chemotherapy and radiotherapy","volume":"12","author":"Xiang","year":"2020","journal-title":"Epigenomics"},{"key":"10.1016\/j.canlet.2021.09.015_bib12","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1016\/j.ymthe.2020.09.007","article-title":"Adenylate kinase 4 modulates the resistance of breast cancer cells to tamoxifen through an m6A-based epitranscriptomic mechanism","volume":"28","author":"Liu","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2021.09.015_bib13","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s12276-020-00510-w","article-title":"METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner","volume":"53","author":"Pan","year":"2021","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.canlet.2021.09.015_bib14","doi-asserted-by":"crossref","first-page":"11366","DOI":"10.1111\/jcmm.15738","article-title":"METTL3 potentiates resistance to cisplatin through m(6) A modification of TFAP2C in seminoma","volume":"24","author":"Wei","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.canlet.2021.09.015_bib15","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41419-020-03148-8","article-title":"The mechanism of m6A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by \u03b2-elemene","volume":"11","author":"Liu","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2021.09.015_bib16","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-019-0830-6","article-title":"m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis","volume":"12","author":"Jin","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2021.09.015_bib17","first-page":"621","article-title":"The epitranscriptome m6A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells","volume":"52","author":"Taketo","year":"2018","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.canlet.2021.09.015_bib18","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019103181","article-title":"RNA m6A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy","volume":"39","author":"Lin","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2021.09.015_bib19","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/423239","article-title":"BRAF in melanoma: pathogenesis, diagnosis, inhibition, and resistance","author":"Sullivan","year":"2011","journal-title":"J Skin Cancer"},{"key":"10.1016\/j.canlet.2021.09.015_bib20","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/nm.3392","article-title":"Tumor adaptation and resistance to RAF inhibitors","volume":"19","author":"Lito","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2021.09.015_bib21","first-page":"505","article-title":"BRAF inhibitors and melanoma","volume":"17","author":"Flaherty","year":"2011","journal-title":"Canc. J."},{"key":"10.1016\/j.canlet.2021.09.015_bib22","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.1158\/0008-5472.CAN-11-1243","article-title":"Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options","volume":"71","author":"Villanueva","year":"2011","journal-title":"Canc. Res."},{"key":"10.1016\/j.canlet.2021.09.015_bib23","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1186\/s12885-019-6175-2","article-title":"Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting","volume":"19","author":"Carroll","year":"2019","journal-title":"BMC Canc."},{"key":"10.1016\/j.canlet.2021.09.015_bib24","article-title":"Characterization of melanoma cell lines resistant to vemurafenib and evaluation of their responsiveness to EGFR- and MET-inhibitor treatment","volume":"21","author":"Dratkiewicz","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2021.09.015_bib25","doi-asserted-by":"crossref","first-page":"6537","DOI":"10.21873\/anticanres.13869","article-title":"All-<em>trans<\/em> retinoic acid overcomes acquired resistance to PLX4032 <em>via<\/em> inhibition of PIN1 in melanoma cells","volume":"39","author":"Kim","year":"2019","journal-title":"Anticancer Res."},{"key":"10.1016\/j.canlet.2021.09.015_bib26","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ccell.2014.11.018","article-title":"Tunable-combinatorial mechanisms of acquired resistance limit the efficacy of BRAF\/MEK cotargeting but result in melanoma drug addiction","volume":"27","author":"Moriceau","year":"2015","journal-title":"Canc. Cell"},{"key":"10.1016\/j.canlet.2021.09.015_bib27","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.molcel.2016.03.021","article-title":"The m(6)A methyltransferase METTL3 promotes translation in human cancer cells","volume":"62","author":"Lin","year":"2016","journal-title":"Mol. Cell"},{"key":"10.1016\/j.canlet.2021.09.015_bib28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1479-5876-10-85","article-title":"The role of BRAF V600 mutation in melanoma","volume":"10","author":"Ascierto","year":"2012","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2021.09.015_bib29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1158\/1535-7163.MCT-10-0799","article-title":"BRAFV600E: implications for carcinogenesis and molecular therapy","volume":"10","author":"Cantwell-Dorris","year":"2011","journal-title":"Mol. Canc. Therapeut."},{"key":"10.1016\/j.canlet.2021.09.015_bib30","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1002\/cncr.25261","article-title":"BRAF, a target in melanoma: implications for solid tumor drug development","volume":"116","author":"Flaherty","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2021.09.015_bib31","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/nature13121","article-title":"Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma","volume":"508","author":"Sun","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.09.015_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18071527","article-title":"Role played by signalling pathways in overcoming BRAF inhibitor resistance in melanoma","volume":"18","author":"Chan","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2021.09.015_bib33","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1158\/2159-8290.CD-12-0386","article-title":"Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma","volume":"3","author":"Girotti","year":"2013","journal-title":"Canc. Discov."},{"key":"10.1016\/j.canlet.2021.09.015_bib34","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.advenzreg.2006.01.004","article-title":"Roles of the RAF\/MEK\/ERK and PI3K\/PTEN\/AKT pathways in malignant transformation and drug resistance","volume":"46","author":"McCubrey","year":"2006","journal-title":"Adv. Enzym. Regul."},{"key":"10.1016\/j.canlet.2021.09.015_bib35","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.09.015_bib36","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.cell.2017.05.045","article-title":"Dynamic RNA modifications in gene expression regulation","volume":"169","author":"Roundtree","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2021.09.015_bib37","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/s41580-019-0168-5","article-title":"Reading, writing and erasing mRNA methylation","volume":"20","author":"Zaccara","year":"2019","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2021.09.015_bib38","first-page":"6763","article-title":"EGFR inhibition enhances the antitumor efficacy of a selective BRAF V600E inhibitor in thyroid cancer cell lines","volume":"15","author":"Jia","year":"2018","journal-title":"Oncol Lett"},{"key":"10.1016\/j.canlet.2021.09.015_bib39","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s41586-021-03536-w","article-title":"Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia","volume":"593","author":"Yankova","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2021.09.015_bib40","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1038\/jid.2011.147","article-title":"Mechanisms of resistance to RAF inhibitors in melanoma","volume":"131","author":"Aplin","year":"2011","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.canlet.2021.09.015_bib41","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1002\/cncr.30435","article-title":"Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma","volume":"123","author":"Lim","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2021.09.015_bib42","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1056\/NEJMoa1408868","article-title":"Combined vemurafenib and cobimetinib in BRAF-mutated melanoma","volume":"371","author":"Larkin","year":"2014","journal-title":"N. Engl. J. Med."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521004626?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383521004626?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:58:23Z","timestamp":1759593503000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383521004626"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":42,"alternative-id":["S0304383521004626"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2021.09.015","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"METTL3 induces PLX4032 resistance in melanoma by promoting m6A-dependent EGFR translation","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2021.09.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}